SPM: Niche pharmaceutical franchise with weak recent earnings and limited liquid upside
Intrinsic value VND 11,434 vs market VND 10,200 — implied upside 12.1% (model confidence: low).
Business Overview
Công ty Cổ phần S.P.M operates in the Vietnamese pharmaceuticals segment (ICB: Dược phẩm) listed on HOSE. The company has 13,770,000 shares outstanding and generates revenues from pharmaceutical product sales across marketed lines. Over the past three years reported revenue declined from VND 406.1 bn in 2023 to VND 254.0 bn in 2025, reflecting contraction in scale. Gross margin remains healthy at 24.0% despite falling top-line.
Investment Thesis
SPM’s valuation (DCF-based intrinsic value VND 11,434 per share) implies modest upside of 12.1% to the current price of VND 10,200, but the model carries low confidence. Strengths include a healthy gross profit margin of 24.0% and low leverage (Debt/Equity 0.17). Ownership is concentrated: the largest shareholder holds 45.0% and the top five collectively account for roughly 75%—this supports strategic stability but raises liquidity and minority-interest considerations. Weaknesses are material: revenue has contracted by -13.3% YoY most recently, net profit turned negative in 2025 (VND -1.7 bn) after VND 4.6 bn in 2024, producing ROE of -0.2% and EPS of VND -123 per share. Earnings quality is middling at 54.1/100, and two model sanity flags note illiquidity and an upside cap tied to low trading volumes (average 2-week volume 2,774 shares). The implied upside (12.1%) is inside a moderate range but insufficiently large given execution risk and the low confidence in the model inputs (historical growth blend with historical CAGR -28.6% and terminal growth 4.0%).
Valuation Commentary
Blended DCF-dominant approach (70% DCF, 30% PE cap) with a 10-year projection and terminal growth of 4.0%.
- Base free cash flow used: VND 47,665,969,464 (model input labeled base_fcf).
- WACC set at 10.0% (ke 11.1%, kd after-tax 5.26%, equity weight 79.67%).
- Terminal growth rate: 4.0%; terminal value contribution: 57.07% of enterprise value.
- Net debt included: VND 69,358,049,779.
- Model blend: DCF weight 0.7, PE component capped (PE cap 25) but PE intrinsic not provided.
The DCF-driven intrinsic VND 11,434 implies 12.1% upside to the current price, but model confidence is low and the intrinsic per-share DCF input (raw_intrinsic_value VND 54,963.8 in inputs) required calibration. Illiquidity flags and a negative recent earnings trend reduce conviction. Treat the target as indicative rather than precise; upside is not large enough to offset execution and liquidity risk without clearer earnings recovery.
Bull vs Bear
- Recovering revenue and margins would leverage a healthy gross margin of 24.0% into positive net profit and EPS recovery from VND -123 to positive territory.
- Low leverage (Debt/Equity 0.17) provides flexibility to fund working capital or targeted marketing to regain market share without heavy balance-sheet strain.
- High insider ownership (largest holder 45.0%) can enable fast strategic action and alignment on turnaround measures.
- DCF inputs assume a sustainable terminal growth of 4.0%; if management restores growth above this, intrinsic value would re-rate upward.
- Revenue has fallen from VND 406.1 bn in 2023 to VND 254.0 bn in 2025 (three-year decline), with Revenue YoY -13.3%, indicating secular or competitive pressures.
- Net profit turned negative in 2025 (VND -1.7 bn) after VND 4.6 bn in 2024; ROE is negative at -0.2% and EPS is VND -123, indicating weak near-term profitability.
- Market liquidity is poor (avg 2-week volume 2,774 shares) and the model flagged illiquid and illiquid_upside_capped, limiting ability for funds to enter/exit without price impact.
- Ownership concentration (top holder 45.0%) increases control risk for minorities and could limit corporate governance transparency.
Sector Context
The Vietnamese pharmaceuticals sector faces intense competition, pricing pressure from generics, and dependence on distribution access. VAS accounting differences can affect reported margins and working capital timing relative to international comparables. Peers show mixed valuations: sector median implied upside is 12.0% (351 peers), with top peer implied upsides above 36% while some small peers show very negative repricing. Foreign ownership room for SPM is non-trivial (foreign_room ~6,466,018 shares) but practical uptake is limited by low turnover. Regulators and SBV credit quotas are less directly relevant here than for banks, but SOE-related payout or ownership mandates do matter for firms with state shareholders—SPM’s register is dominated by individuals and one bank with 7.6% exposure.
Risk Factors
- Revenue decline and negative 2025 net profit — recent three-year revenue fell from VND 406.1 bn (2023) to VND 254.0 bn (2025); continued shrinkage would impair recovery prospects.
- Low liquidity — avg volume 2,774 shares and model flags 'illiquid' limit tradability and can cap near-term upside realization.
- Concentrated ownership — largest shareholder holds 45.0%, top five ~75%, raising minority shareholder governance and related-party risk.
- Valuation model low confidence — model confidence explicitly 'low' and calibration required (isotonic), reducing reliability of the intrinsic number.
- Negative profitability metrics — ROE -0.2%, Net Profit Margin -0.7%, EPS VND -123; absence of dividends (0.0% yield) reduces income investor appeal.
- Exposure to sector pricing and regulatory shifts — reimbursement or procurement changes can quickly affect small pharma players' margins.
Catalysts
- Evidence of top-line stabilization or re-acceleration (quarterly revenue growth reversing the recent decline).
- Return to profitability in quarterly results (net profit turning positive from VND -1.7 bn in 2025).
- Corporate actions that improve liquidity or minority protections (secondary listing, block trades, or a broader free-float increase).
- Clear strategic initiative (new product launches or distribution deals) that materially alters the growth trajectory vs the historical CAGR of -28.6% used in the blend.
Forensic Assessment
No Beneish M-Score is provided (mscore null) and there are no explicit forensic red flags in the input. Earnings quality is moderate at 54.1/100. Given the absence of M-Score and red-flag entries, there is no immediate forensic alarm, but concentrated ownership and recent profit volatility justify ongoing monitoring of related-party transactions and accounting note details.
Track Record
Model track record spans 12 years with a hit rate of 36.4% (historical directional calls >10% matched the subsequent year in just over one-third of years). Average historical upside where the model has been right was 59.5%. The low hit rate suggests limited predictive reliability for SPM specifically; treat model outputs as one input among fundamental and liquidity considerations rather than a high-confidence signal.
Written by a language model on 2026-08-10 from this page’s own model outputs and financial statements, and may quote figures from that date. Descriptive analysis, not investment advice — no buy, sell or hold recommendation is given or implied.